The high cost of spasticity in multiple sclerosis to individuals and society

@article{Stevenson2015TheHC,
  title={The high cost of spasticity in multiple sclerosis to individuals and society},
  author={Valerie L Stevenson and Adrien Gras and J Bardos and Julie Broughton},
  journal={Multiple Sclerosis Journal},
  year={2015},
  volume={21},
  pages={1583 - 1592}
}
Background: Spasticity is an extremely common, distressing and disabling symptom of multiple sclerosis. Limited data suggest the associated health care costs correlate with increasing severity and place a high economic burden on individuals, health care systems and society. Objective: The aim of this study was to quantify the impact of multiple sclerosis spasticity on health care resources and the associated costs at different levels of severity in people with multiple sclerosis in the United… 
View on SAGE
msj.sagepub.com
19 Citations
Background Citations
7
Methods Citations
1

19 Citations

Citation Type

Citation Type

Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study
TLDR
Spasticity had a clear impact on patients' and caregivers' lives, including the ability to work and injection costs, and the greatest patient-reported challenges were the cost and availability of timely appointments.
Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study (Preprint)
TLDR
Spasticity had a clear impact on patients' and caregivers' lives, including the ability to work and injection costs, and the greatest patient-reported challenges were the cost and availability of timely appointments.
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis
TLDR
The use of Sativex could improve the quality of life of patients with a reasonable incremental cost resulting as a cost-effective option for patients with MS-resistant spasticity, according to the cost-effectiveness acceptability curve.
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study
TLDR
Botulinum toxin was used for spasticity and its consequences from the early stages of MS, without significant adverse effects, and MS-specific goals and injection characteristics can be used to refer MS patients to BT treatment and to guide the design of future clinical trials and observational studies.
Effects of shiatsu on the health-related quality of life of a person with secondary progressive multiple sclerosis: A mixed methods N-of-1 trial within a whole systems research case study
Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions.
Therapeutic Benefit of Botulinum Toxin a (Incobotulinum Toxin) for the Treatment of Spasticity of the Triceps Surae in Multiple Sclerosis: An Observational Study
TLDR
This observational study confirms the benefit of treating spasticity in multiple sclerosis with the incobotulinum toxin, with a functional objective, and additional studies are required to specify more precisely the place of botulinum toxins in the treatment of spasticsity in patients suffering from multiple sclerosis.
Prevalence of unmet needs for spasticity management in care home residents in the East Midlands, United Kingdom: a cross-sectional observational study
TLDR
Care home residents in this study had high levels of unmet need for spasticity management, most frequently related to the risk of contracture development or problems with skin hygiene or integrity in the upper limb.
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis
TLDR
The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included.
Does acupuncture help patients with spasticity? A narrative review.
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
Multiple sclerosis spasticity daily management: retrospective data from Europe
  • T. Berger
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2013
TLDR
The condition is largely undertreated because current treatment options do not provide adequate control of MS spasticity, and newer drugs that can provide better symptomatic relief and may slow progression to more severe forms of disability will be a step forward in the level of care for MS patients.
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
TLDR
MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severeSpasticity causes high costs that increase with increasing severity, and the health insurance costs showed the same trend.
Prevalence and treatment of spasticity reported by multiple sclerosis patients
TLDR
In the focused survey, ITBG reported lower levels of spasticity than ORALG, less stiffness in the legs, less pain and fewer spasms at any time, which can significantly impact QOL parameters by reducing spasms, pain and fatigue.
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice
  • C. Pozzilli
  • Medicine, Psychology
    Expert review of neurotherapeutics
  • 2013
TLDR
Sativex appears to be a promising solution for a meaningful proportion of patients with MS-related spasticity who have inadequate response to current antispasticity medications and interim data from safety registries in the UK and Spain indicate a low risk for serious adverse drug reactions.
The management of multiple sclerosis patients.
The management of individuals with multiple sclerosis must be considered under the following headings: administration and follow-up of adequate disease-modifying treatment, symptomatic relief and…
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines
TLDR
The Spanish Society of Neurology demyelinating diseases working group has developed a consensus document on spasticity in patients with MS, and plans are currently in motion to develop next-level European guidelines through a concerted approach coordinated by the European Federation of Neurological Societies.
Sativex® in multiple sclerosis spasticity: a cost–effectiveness model
  • J. Slof, A. Gras
  • Medicine
    Expert review of pharmacoeconomics & outcomes research
  • 2012
TLDR
The incremental cost of Sativex was low compared with current spasticity treatments, and provided a quality-adjusted life-year gain over the current standard of care, despite having a relatively high acquisition cost.
Anti-spasticity agents for multiple sclerosis.
TLDR
The rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive, validated spasticity measures need to be developed.
Spasticity management in multiple sclerosis.
  • C. Hughes, I. Howard
  • Medicine
    Physical medicine and rehabilitation clinics of North America
  • 2013
Costs and quality of life in multiple sclerosis patients with spasticity
TLDR
The purpose of this study was to obtain estimates of resource utilization, costs, and HRQoL, for patients with different levels of MS spasticity in southern Sweden.
...
1
2
3
...